Home|Journals|Articles by Year|Audio Abstracts RSS - TOC

Case Report

IJMDC. 2017; 1(2): 85-87

Effectiveness of apixaban in warfarin hepatotoxicity: A case report

Ali A Alaklabi, Abdullah M Alotaibi, Abdulmalik S Alotaibi, M Alessa, Hanan Abdulrahman Habeeb.


Background: Apixaban is a direct and competitive inhibitor of factor Xa. It has been shown to be effective and safe to Prevent Stroke in Atrial Fibrillation Patients. This study is a case report of warfarin-induced cholestasis that occurred one week after starting warfarin for deep venous thrombosis, in which the cholestasis improved after the offending drug was stopped but worsened after beginning apixaban.
Case Presentation: We presented a case of 79-year-old woman, she was presented to the emergency depart¬ment with a chief complaint of left lower limb swelling of 3 days duration. On physical examination, her left lower limb was swollen, warm, and tender. Venous Doppler ultrasound showed extensive deep venous throm¬bosis and anticoagulation with unfractionated heparin and warfarin 7 mg initiated.
Conclusion: Apixaban should be avoided in patients with warfarin-induced cholestasis.

Key words: Warfarin, apixaban, hepatotoxicity, anticoagulant, thrombosis, case report.

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.